These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 29746198)
1. The use of placebos in controlled trials of surgical interventions: a brief history. Wartolowska KA; Beard DJ; Carr AJ J R Soc Med; 2018 May; 111(5):177-182. PubMed ID: 29746198 [No Abstract] [Full Text] [Related]
2. [Roaming through methodology. XXIII. The need for randomization and blinding in therapeutic investigations]. Dorhout Mees EJ Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2228. PubMed ID: 11103264 [No Abstract] [Full Text] [Related]
3. [Exploration of the placebo control issue in clinical trials of anti-cancer drugs]. Chen XY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):398-400. PubMed ID: 19799093 [No Abstract] [Full Text] [Related]
4. General design issues in efficacy, equivalency and superiority trials. Fleiss JL J Periodontal Res; 1992 Jul; 27(4 Pt 2):306-13; discussion 323-7. PubMed ID: 1507018 [TBL] [Abstract][Full Text] [Related]
9. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. de la Fuente-Fernández R; Schulzer M; Stoessl AJ Biol Psychiatry; 2004 Jul; 56(2):67-71. PubMed ID: 15231437 [TBL] [Abstract][Full Text] [Related]
10. The placebo effect: why we should care. Tausk F; Ader R; Duffy Smith N Clin Dermatol; 2013; 31(1):86-91. PubMed ID: 23245979 [TBL] [Abstract][Full Text] [Related]
11. The landscape and lexicon of blinding in randomized trials. Schulz KF; Chalmers I; Altman DG Ann Intern Med; 2002 Feb; 136(3):254-9. PubMed ID: 11827510 [No Abstract] [Full Text] [Related]
12. Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained. Holmgren EB J Biopharm Stat; 1999 Nov; 9(4):651-9. PubMed ID: 10576409 [TBL] [Abstract][Full Text] [Related]
13. The quality of placebos used in randomized, controlled trials of lumbar and pelvic joint thrust manipulation-a systematic review. Puhl AA; Reinhart CJ; Doan JB; Vernon H Spine J; 2017 Mar; 17(3):445-456. PubMed ID: 27888138 [TBL] [Abstract][Full Text] [Related]
14. Randomization as a basis for inference in noninferiority trials. Wiens BL Pharm Stat; 2006; 5(4):265-71. PubMed ID: 17128425 [TBL] [Abstract][Full Text] [Related]
15. General issues in efficacy, equivalency, and superiority trials: clinical considerations. Listgarten MA J Periodontal Res; 1992 Jul; 27(4 Pt 2):314-9. PubMed ID: 1507019 [TBL] [Abstract][Full Text] [Related]
16. N of 1 trials. Placebos should be abandoned. Treasure W BMJ; 1996 Aug; 313(7054):427-8. PubMed ID: 8761253 [No Abstract] [Full Text] [Related]
17. Randomized placebo-controlled cross-over designs in clinical trials: a gold standard to be reassessed. Leonard G; Lafrenaye S; Goffaux P Curr Med Res Opin; 2012 Feb; 28(2):245-8. PubMed ID: 22208674 [TBL] [Abstract][Full Text] [Related]
18. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]